Señales en vivo de ALZCUR.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 10:45):

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system...

Stats
Volumen de hoy	88 719.00
Volumen promedio	76 290.00
Capitalización de mercado	178.81M
EPS	SEK0 ( 2024-04-25 )
Próxima fecha de ganancias	( SEK0 ) 2024-05-02
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-3.62
ATR14	SEK0.0300 (1.56%)

Volumen Correlación

Largo: 0.09 (neutral)

Corto: -0.45 (neutral)

Signal:(48.703) Neutral

AlzeCure Pharma AB (publ) Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AlzeCure Pharma AB (publ) Correlación - Moneda/Commodity

-0.77
( moderate negative )

0.00
( neutral )

-0.75
( moderate negative )

0.73
( moderate )

0.72
( moderate )

AlzeCure Pharma AB (publ) Finanzas

Annual	2023
Ingresos:	SEK0
Beneficio Bruto:	SEK-476 000 (0.00 %)
EPS:	SEK-0.560

FY	2023
Ingresos:	SEK0
Beneficio Bruto:	SEK-476 000 (0.00 %)
EPS:	SEK-0.560

FY	2022
Ingresos:	SEK0
Beneficio Bruto:	SEK-570 000 (0.00 %)
EPS:	SEK-1.170

FY	2021
Ingresos:	SEK0.00
Beneficio Bruto:	SEK0.00 (0.00 %)
EPS:	SEK-1.999

Financial Reports:

No articles found.

AlzeCure Pharma AB (publ)

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.

Actualizaciones en tiempo real para AlzeCure Pharma AB (publ) [ALZCUR.ST]

Upcoming Earnings Alert